Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification
China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...
Potential first-in-class
Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU
China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca
China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...
Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...
Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes
Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...
Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy
Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has...
Jiangsu Alpha Biopharma’s Zorifertinib NDA Accepted for Review by CDE
China-based Jiangsu Alpha Biopharma Ltd has announced that the New Drug Application (NDA) for its...
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...
Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485
China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...
Immune-Onc Therapeutics Completes $131 Million Series B Financing
US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
Duality Biologics, a developer of novel modality drugs operating in the United States and China,...
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China
Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...